BCR-ABL-IN-7
Modify Date: 2024-04-05 18:38:22
BCR-ABL-IN-7 structure
|
Common Name | BCR-ABL-IN-7 | ||
|---|---|---|---|---|
| CAS Number | 688050-42-2 | Molecular Weight | 385.41 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C19H16FN3O3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BCR-ABL-IN-7BCR-ABL-IN-7 (compound 4) is a WT and T315I mutant ABL kinases inhibitor. BCR-ABL-IN-7 effectively inhibits activities of WT and T315I mutant ABL kinases. BCR-ABL-IN-7 can be used for the research of chronic myeloid leukemia (CML) research[1]. |
| Name | WAY-328158 |
|---|---|
| Synonym | More Synonyms |
| Description | BCR-ABL-IN-7 (compound 4) is a WT and T315I mutant ABL kinases inhibitor. BCR-ABL-IN-7 effectively inhibits activities of WT and T315I mutant ABL kinases. BCR-ABL-IN-7 can be used for the research of chronic myeloid leukemia (CML) research[1]. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C19H16FN3O3S |
|---|---|
| Molecular Weight | 385.41 |
| 3-Isoxazolecarboxamide, N-[3-(aminocarbonyl)-4,5,6,7-tetrahydrobenzo[b]thien-2-yl]-5-(4-fluorophenyl)- |